Global medical aesthetic corporations CLASSYS said on the 13th that last year's revenue rose 38% from a year earlier to 336.8 billion won, while operating profit increased 39% to 170.6 billion won. The operating margin was 50.7%.
Fourth-quarter revenue was 93.4 billion won, with quarterly revenue surpassing 90 billion won for the first time. Overseas sales accounted for 70% (65.7 billion won), and fourth-quarter overseas revenue rose 33% from the same period a year earlier. Fourth-quarter operating profit also exceeded 50 billion won for the first time, showing continued step-wise growth, the company said.
Despite higher depreciation from the merger with Ilooda, the company said it maintained industry-leading profitability and entered a phase where fixed-cost leverage is being fully reflected.
CLASSYS signed a deal last year to acquire its local distributor in Brazil and is shifting the Latin American market to a directly managed model. When the transaction is completed at the end of this month as scheduled, local revenue and profit and loss will be recognized directly.
The company expected the growth rate to widen starting this year. In addition to the impact of switching to direct operations in major South American countries and Japan, the company said there are various growth drivers, including: △ Shurink and Volnewmer's entry into China over the next 2 to 3 years, △ Shurink's entry into the United States, △ increased market share in Europe, △ growth of new devices such as QuadSayi and Lipot, and △ growth in home devices.
The company presented a revenue outlook (guidance) of up to 510 billion won for this year. A CLASSYS official said, "Backed by diverse growth drivers by product and region, our goal this year is to achieve up to 510 billion won in revenue," adding, "In particular, Volnewmer is expected to establish itself as a global mega-hit product starting this year, and we will continue to push for direct operations in countries with high market attractiveness and the launch of new devices."